An interventional study of Dried Plum and Calcium supplement in Postmenopausal Osteoporosis, sponsored by Penn State University. Active, not recruiting at 1 site in United States. Open to female participants aged 55 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Penn State University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Osteoporosis, Postmenopausal with a site in United States — 4 open to participants now, 11 under way, 1 of them phase 3. Osteoporosis, Postmenopausal · United States.
Among the 106 studies in Osteoporosis, Postmenopausal with a site in United States, this one is the 35th largest by enrollment of the 95 interventional ones that give a count, is one of 3 that started in 2016, is one of 16 with no phase, reaches primary completion later than 7 of the 10 other live ones, and was the 73rd registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →4 of the 106 studies in Osteoporosis, Postmenopausal with a site in United States are open now. Recruiting first, the newest first:
University of Connecticut · Sites in United States
Ages 45–70 · Women only · Healthy volunteers
Penn State University · Sites in United States
Ages 44–55 · Women only · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 45+ · Women only · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 45+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 55 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 30 · Phase 4 31
First in 1994; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 322 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 201 across the 95 interventional studies, 101 across the 8 observational. Of the 92 that completed or were terminated, 49 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 106 have an industry lead sponsor. The 10 most frequent:
Penn State University is the lead sponsor of 271 studies on the registry; 54 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 11 (73%) have results posted.
Penn State University has 2 studies filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
4 of the studies in Osteoporosis, Postmenopausal with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06577935Angitia BiopharmaceuticalsA Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) | 2026-12 |
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
| NCT05010590Massachusetts General HospitalAnabolic Therapy in Postmenopausal Osteoporosis | 2027-10-01 |
| NCT06558188Massachusetts General HospitalCombined Anabolic Therapy | 2027-11-02 |
Add all 4 to your calendar (.ics) → With an account.
Among the 106 studies in Osteoporosis, Postmenopausal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Postmenopausal women often seek non-pharmacologic interventions for the protection of bone health. Previous research in humans and rodents has indicated that dietary dried plum consumption may be beneficial for bone health, especially in postmenopausal women. However, it is unknown in what quantity dried plums need to be consumed to be of benefit and through what mechanisms dried plums act to impact bone health. Therefore, the purpose of this study is to evaluate the impact of 52 weeks of dried plums consumption in varying quantities on bone mineral density (BMD), bone geometry, and estimated bone strength in postmenopausal women. The investigators also seek to evaluate the mechanisms underlying the effects of dried plums as a dietary supplement by assessing polyphenols and the bioavailable conjugated metabolites in the urine of postmenopausal women taking different doses of dietary dried plums. The investigators aim to further investigate the mechanisms of dried plum action on bone by measuring markers of bone metabolism in response to dried plum consumption.
Given the current high incidence of osteoporosis, reducing the risk of osteoporosis development is essential. Recent estimates, based on the 2010 US Census, indicate that approximately 10.3 million people age 50 and older have osteoporosis. By 2030 the prevalence of osteoporosis for women 50 years and older is projected to reach 13.6 million. Postmenopausal osteoporosis is characterized not only by hypoestrogenism, but also by increased production of reactive oxygen species, oxidative stress, and inflammatory response. Current first line strategies are treatment of osteoporosis with pharmacologic approaches. Complementary recommendations include the maintenance of calcium (Ca2+) and vitamin D (VitD) intake to meet the current recommendations. Although the anti-resorptive therapies are effective they are also associated with an array of negative side effects, which reduce patient compliance to use of the therapy.
Non-pharmacologic options to reducing the risk of bone loss are becoming more attractive to many postmenopausal women. The phenolics and bioavailable conjugated metabolites found in dried plums are proposed to modulate the inflammatory signaling pathways and have the potential to influence bone formation and bone resorption, thus modulating the risk of bone loss. The investigators are conducting a 52 week dose ranging randomized controlled trial that builds upon previous rodent and human work and addresses the experimental design limitations of the previous work, to assess bone outcomes with clinical (BMD) and mechanistic (bone geometry, bone metabolism markers, and inflammation markers) techniques. Additionally, this study will include a detailed assessment of the phenolics in the dried plums to explore the relationship between these compounds and bone outcomes.
Participants will participate in a 1-2 week screening period followed by a 1-2 week baseline period. At the end of baseline randomization to 1 of 3 groups will occur (Ca2+ and VitD only; 50g Dried Plums/day and Ca2+ and VitD; 100g Dried Plums/day and Ca2+ and VitD). Dried plums and Calcium/Vitamin D supplements will be provided to participants for the duration of the intervention. At the beginning of the 52 week intervention participants will begin consumption of dried plums and will be given a run in period where the number of dried plums consumed per day increases slowly to minimize the side effects felt by the participants. The dried plums will be consumed as snacks in the morning, midday, and in the evening. Participants will visit the laboratory for testing every 4 weeks during the 52 week intervention, with more testing occurring during weeks 12, 24, 36, and 52 than the other testing periods.
At testing period visits participants will be asked to complete some or all of the following: body weight measurement; blood sampling; 24-hour urine collection; stool sample collection; DXA scan; peripheral quantitative computed tomography (pQCT) scan; completion of health, physical activity, and nutrition questionnaires; completion of supplement/symptom, diet, and physical activity logs.
A total of 300 participants will be enrolled and screed with an expected randomization of 79 participants per group. The investigators anticipate a 20% drop-out rate between baseline and week 52, thus will anticipate having a final sample size of 63 participants per group complete the study. This sample size provides over 80% power to detect differences with the primary BMD, bone geometry, and bone strength variables.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of the following agents affecting bone metabolism:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Participants will be asked to refrain from consumption of dried plums for the duration of the intervention (52 weeks).
Dietary Supplement: Calcium supplement · Dietary Supplement: Vitamin D supplement
Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 6 (50g) dried plums per day for the duration of the intervention (52 weeks).
Dietary Supplement: Dried Plum · Dietary Supplement: Calcium supplement · Dietary Supplement: Vitamin D supplement
Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 12 (100g) dried plums per day for the duration of the intervention (52 weeks).
Dietary Supplement: Dried Plum · Dietary Supplement: Calcium supplement · Dietary Supplement: Vitamin D supplement
Participants randomized to the 50g dried plum group will consume 6 dried plums per day for the duration of the 52 week intervention. Participants randomized to the 100g dried plum group will consume 12 dried plums per day for the duration of the 52 week intervention.
Also known as: Prunes
All participants will consume calcium supplements for the duration of baseline and intervention.
All participants will consume vitamin D supplements for the duration of baseline and intervention.
Percent change from baseline in areal bone mineral density (via DXA) of the lumbar spine, total hip, and femoral neck
Percent change in areal BMD measured during screening, and weeks 24 and 52 of the 52 week dietary intervention at the lumbar spine, total hip, and femoral neck.
Time frame: at screening, week 24, and week 52
Percent change from baseline in DXA hip structural analysis
Percent change in hip structural analysis (HSA) measured during screening, and weeks 24 and 52 of the 52 week dietary intervention at the total hip.
Time frame: at screening, week 24, and week 52
Percent change from baseline in DXA spine trabecular bone score
Percent change in trabecular bone score (TBS) measured during screening, and weeks 24 and 52 of the 52 week dietary intervention at the lumbar spine.
Time frame: at screening, week 24, and week 52
Percent change from baseline in pQCT volumetric BMD of the tibia and radius
Percent change in volumetric BMD, cortical and trabecular compartments, measured during baseline, and weeks 24 and 52 of the 52 week dietary intervention at the tibia and radius. The combination of measurements will provide an overall picture of the 3-dimensional structure of a weight bearing (tibia) and non-weight bearing (radius) site and how the sites are impacted by the intervention.
Time frame: at baseline, week 24, and week 52
Percent change from baseline in pQCT geometry measurements of the tibia and radius
Percent change in bone geometry estimates measured during baseline, and weeks 24 and 52 of the 52 week dietary intervention at the tibia and radius. The combination of measurements will provide an overall picture of the 3-dimensional structure of a weight bearing (tibia) and non-weight bearing (radius) site and how the sites are impacted by the intervention.
Time frame: at baseline, week 24, and week 52
Percent change from baseline in pQCT strength measurements of the tibia and radius
Percent change in bone strength estimates measured during baseline, and weeks 24 and 52 of the 52 week dietary intervention at the tibia and radius. The combination of measurements will provide an overall picture of the 3-dimensional structure of a weight bearing (tibia) and non-weight bearing (radius) site and how the sites are impacted by the intervention.
Time frame: at baseline, week 24, and week 52
Change from baseline in bone turnover markers
Change in serially-sampled fasting serum concentrations of bone formation (N-terminal type 1 procollagen; P1NP) and bone resorption (crosslaps; CTx) before, during and after the dietary intervention. The combined measures will provide information regarding changes in the rate of bone resorption and bone formation.
Time frame: at baseline, week 12, week 24, week 36, and week 52
Change from baseline in cellular bone metabolism
Change in serially-sampled fasting serum concentrations of bone signaling markers (i.e., Insulin like growth factor-1 \[IGF-1\], osteoprotegerin \[OPG\], receptor activator of nuclear factor kappaB ligand \[RANKL\], and sclerostin \[SOST\]) before, during and after the dietary intervention. Changes in these variables will assist in understanding the underlying mechanisms behind changes in the rates of bone resorption and bone formation.
Time frame: at baseline, week 12, week 24, week 36, and week 52
Change from baseline in urine phenolic concentrations
Change in serially-sampled 24 hour urine concentrations of phenolic compounds attributable to dried plum consumption.
Time frame: at baseline and every 4 weeks during the intervention
Change from baseline in serum phenolic concentrations
Change in serially-sampled fasting serum concentrations of phenolic compounds attributable to dried plum consumption.
Time frame: at baseline, week 12, week 24, week 36, and week 52
Change from baseline in expression of inflammatory markers
Change in peripheral blood mononuclear cell (PBMC) gene expression of inflammatory markers before, during and after the dietary intervention. Additionally, the relationship between the changes in gene expression of inflammation markers and bone outcomes will be explored. The combined changes of the gene expression of inflammatory markers will provide a comprehensive picture of the inflammatory environment of the participants before, during and following the dietary intervention. This comprehensive picture will assist in understanding the mechanisms by which the inflammatory environment contributes to bone loss in postmenopausal women and how the dietary intervention impacts these factors.
Time frame: at baseline, week 12, week 24, week 36, and week 52
Change from baseline in gut microbiome
Serially-sampled stool samples for assessment of changes in the gut microbiome before, during and after the dietary intervention. Additionally, the relationship between the changes in the gut microbiome and bone outcomes will be explored.
Time frame: at baseline, week 24, and week 52
Started Jun 2016 (actual). Primary completion is estimated for Dec 2027, 138 months after the start.
Of 48 non-industry interventional studies with no phase under Osteoporosis, Postmenopausal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's planned 138 months is above that.
Counting every sponsor, half of 51 studies reached it within 17 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prune
Osteoporosis, Postmenopausal →